Scilex (SCLX) Competitors

Scilex (NASDAQ:SCLX) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Do analysts prefer SCLX or HURA?

Scilex currently has a consensus price target of $455.00, suggesting a potential upside of 8,039.53%. TuHURA Biosciences has a consensus price target of $12.67, suggesting a potential upside of 376.19%. Given Scilex's higher probable upside, equities analysts plainly believe Scilex is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
TuHURA Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the media favor SCLX or HURA?

In the previous week, TuHURA Biosciences had 7 more articles in the media than Scilex. MarketBeat recorded 9 mentions for TuHURA Biosciences and 2 mentions for Scilex. Scilex's average media sentiment score of 0.94 beat TuHURA Biosciences' score of 0.48 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	0 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor SCLX or HURA?

Scilex received 8 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 86.67% of users gave Scilex an outperform vote.

Company	Underperform	Outperform
Scilex	Outperform Votes 13 86.67%	Underperform Votes 2 13.33%
TuHURA Biosciences	Outperform Votes 5 100.00%	Underperform Votes No Votes

Is SCLX or HURA more profitable?

TuHURA Biosciences has a net margin of 0.00% compared to Scilex's net margin of -159.10%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-159.10%	N/A	-93.65%
TuHURA Biosciences	N/A	N/A	-152.88%

Which has better earnings and valuation, SCLX or HURA?

TuHURA Biosciences has lower revenue, but higher earnings than Scilex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$50.71M	0.77	-$114.33M	-$29.02	-0.19
TuHURA Biosciences	N/A	N/A	-$8.32M	N/A	N/A

Which has more volatility & risk, SCLX or HURA?

Scilex has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of SCLX or HURA?

69.7% of Scilex shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 7.9% of Scilex shares are owned by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Scilex beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.